Table 3:

Targeted toxicities associated with NAC infusions (no grade 4-5 toxicities were observed)

CTCAE Term (Reportable Grade)	Dose-Escalation (69 infusions)			Dose-Expansion (48 infusions)*
	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
	n (% of infusions)	n (% of infusions)	n (% of infusions)	n (% of infusions)	n (% of infusions)	n (% of infusions)
Infusion-related reaction (Any)	20 (29)	18 (26)	0 (0)	18 (38)	19 (40)	0 (0)
Flushing	9 (13)	0 (0)	0 (0)	13 (27)	0 (0)	0 (0)
Urticaria	7 (10)	0 (0)	0 (0)	9 (19)	1 (2)	0 (0)
Cough	16 (23)	7 (10)	0 (0)	4 (8)	7 (15)	0 (0)
Dyspnea	0 (0)	5 (7)	0 (0)	2 (4)	0 (0)	0 (0)
Facial Edema	1 (1)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
Bronchospasm	6 (9)	2 (3)	3 (4)	1** (2)	2** (4)	0 (0)
Hypotension	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Allergic reaction (3-5)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Nausea (Any)	9 (13)	2 (3)	0 ()	11 (23)	3 (6)	3 (6)
Vomiting (Any)	13 (19)	2 (3)	0 (0)	22 (46)	7 (15)	1 (2)
Abdominal Pain (Any)	7 (10)	1 (1)	0 (0)	3 (6)	0 (0)	0 (0)
Diarrhea (Any)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Prolonged INR (3-5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Hypofibrinogenemia (3-5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

^*45/48 infusions included final premedication regimen;

^**Subjective throat tightness, no other symptoms.